Background: Incretin hormones; glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have attracted considerable scientific and clinical interest due largely to their insulin-releasing and glucoselowering properties. Dipeptidyl peptidase-4 (DPP-4) is the enzyme responsible for cleavage and inactivation of GIP and GLP-1.
Aim of Study:The present investigation was assigned to study and compare the effect of DPP-4 inhibitor (vildagliptin) on glycemic state in type I and type II diabetes mellitus in rats.Material and Methods: Fifty male albino rats of local strain were used. Rats were divided into three groups: Nondiabetic (10 rats); type I diabetic (non-treated, 10 rats and Vildagliptin-treated, 10 rats); type II diabetic (non-treated group, 10 rats and Vildagliptin-treated, 10 rats). Type I diabetes was induced by a single intraperitoneal injection (60mg/kg) of STZ dissolved in 0.2ml citrate buffer in adult 6 weeks old rats. 48h later fasting blood samples were taken from rat tail and rats with fasting blood glucose levels greater than 250mg/dl were considered diabetic type I. They were left for 30 days before assessment. Type II diabetes was induced by a single intra-peritoneal injection (90mg/kg) of STZ to a group of 2 days old pups. 6 weeks later, fasting blood samples were taken from rat tail and rats with fasting blood glucose level ≥ 160mg/dl were considered as diabetic type II, they were left for 30 days before assessment. In both treated groups rats were treated daily with Vildagliptin (5mg/kg) by oral gavage for 30 days. At the end of the experiment, retro-orbital fasting blood sample was taken for measurement of serum glucose, serum insulin, glycated hemoglobin (HbA1c), plasma GLP-1 levels, lipid profile, malondialdehyde and total antioxidant capacity. Homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated.Results: Serum glucose, blood HbA1c, serum cholesterol, triglycerides (TG), low density lipoprotein-cholesterol (LDLcholesterol) and malondialdehyde (MDA) were significantly higher in type I and type II diabetic non-treated groups when Conclusion: Vildagliptin treatment is a good choice for type II diabetes treatment and has beneficial effects in type I diabetes.